California Pharmacist Winter 2026 - Flipbook - Page 36
Infectious Disease, Urology
Nuzolvence (zoli昀氀odacin)
Nuzolvence is the 昀椀rst-in-class
oral antibiotic for resistant gonorrhea. This spiropyrimidinetrione bacterial type II topoisomerase inhibitor is indicated for
patients weighing ≥35 kg and
requires only 1 oral dose for the
treatment of uncomplicated
urogenital gonorrhea in patients
12 years of age and older. It is
formulated in granules.
Innoviva Therapeutics
12/12/2025
Cardiology
Cardamyst (etripamil)
Cardamyst is an intranasal,
on-demand treatment for
paroxysmal supraventricular
tachycardia (PSVT). This is an
L-type calcium channel blocker
indicated for the conversion of
acute symptomatic episodes of
PSVT to sinus rhythm in adults.
Milestone Pharmaceuticals
12/12/2025
Pulmonology, Immunology
Exdensur (depemokimab-ulaa)
Exdensur is a long-acting interleukin-5 (IL-5) antagonist. This
monoclonal antibody is indicated as an add-on maintenance
treatment for severe asthma
characterized by an eosinophilic
phenotype in adult and pediatric patients 12 years of age
and older. It is the 昀椀rst ultra–
long-acting biologic approved
for dosing every 6 months.
GSK
12/16/2025
Cardiology
Myqorzo (a昀椀camten)
Myqorzo is an oral cardiac
myosin inhibitor for adults with
symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics
12/19/2025
Hematology, Nephrology
Yartemlea (narsoplimab-wuug)
Yartemlea is the 昀椀rst FDA-approved mannan-binding lectin-associated serine protease-2
complement pathway inhibitor
indicated for the treatment of
adults and pediatric patients
2 years of age or older with
hematopoietic stem cell transplant-associated thrombotic
microangiopathy.
Omeros Corporation
12/23/2025
Gastroenterology, Neurology
Nereus (tradipitant)
Nereus is an NK-1 receptor
antagonist indicated for nausea
and pruritus. Itis the 昀椀rst motion
sickness therapy to receive FDA
approval in more than 40 years.
It is an oral neurokinin-1 (NK-1)
receptor antagonist for the
prevention of vomiting induced
by motion in adults.
Vanda Pharmaceuticals
12/30/2025
« ª ¢ ª ª
¤ °ª ª
ª ¡ ±ª
°ª ³³ ª ² ¤
°ª
34
vol. 73, no.1 | California Pharmacist
